Table 1.
Clinical and immunological parameters.
| nnBM | MDS | CMML | sAML | total | |
|---|---|---|---|---|---|
| number | 50 | 106 | 36 | 132 | 324 |
| age (mean) | 20–87 (62) | 25–86 (66) | 31–86 (63) | 26–80 (64) | 20–87 (63) |
| sex (male/female) | 29/21 | 58/48 | 19/17 | 80/52 | 186/138 |
| diagnosis (n) | – | MDS-EB0 (52) MDS-EB1 (33) MDS-EB2 (21) |
CMML-0 (11) CMML-1 (9) CMML-2 (16) |
– | – |
| low clinical risk score intermediate clinical risk score high clinical risk score |
– | 22.1 40.0 37.9 |
8.3% 66.7% 25.0% |
42.4% 18.6% 39.0% |
– |
| HMA treatment (treated/untreated) | – | 23/83 | 6/30 | 13/119 | – |
| alloSCT (treated/untreated) | – | 40/66 | 9/27 | 48/84 | 97/177 |
| genetic data available | – | 63 | 12 | 45 | 120 |
| survival data available | – | 80 | 25 | 111 | 216 |
| HLA-I expression | |||||
| HLA-A,B,C HC H-score (mean) |
190–300 (238) |
110–300 (214) |
70–300 (184) |
10–300 (179) |
10–300 (197) |
| HLA-A,B,C HChigh | 98.0% | 49.1% | 55.6% | 45.5% | 54.5% |
| HLA-E H-score (mean) |
90–220 (171) |
70–200 (132) |
0–280 (135) |
10–260 (108) |
0–280 (130) |
| HLA-F H-score (mean) |
20–300 (175) |
80–300 (170) |
10–300 (160) |
10–380 (145) |
10–300 (158) |
| HLA-G H-score (mean) |
0–6 (1.2) |
0–20 (4.6) |
0–150 (8.5) |
0–250 (20) |
0–250 (11.6) |
| immune cell infiltration (%) | |||||
| TIICs [mean] | 13.1 | 17.1 | 24.9 | 16.8 | 18.5 |
| TILs [mean] | 5.3 | 8.9 | 8.6 | 7.5 | 7.3 |
| T cells (mean) |
0.0–11.9 (4.9) |
0.5–26.1 (7.8) |
0.3–22.1 (6.9) |
0.0–51.1 (5.9) |
0.00–51.1 (5.6) |
| CD3+CD8+ T cells (mean) |
0.0–6.2 (1.9) |
0.2–25.4 (4.7) |
0.1–17.1 (4.4) |
0.0–11.3 (1.4) |
0.0–25.4 (4.5) |
| GrB+ T and NK cells (mean) |
0.0–3.8 (1.4) |
0.1–24.1 (3.6) |
0.1–10.2 (2.9) |
0.0–18.4 (2.5) |
0.0–24.1 (2.8) |
| CD3+FoxP3+ Tregs (mean) |
0.0–0.8 (0.18) |
0.0–5.5 (0.5) |
0.0–7.6 (0.5) |
0.0–3.7 (1.6) |
0.0–6.7 (1.4) |
| MUM1p+ B/plasma cells (mean) |
0.0–3.4 (0.4) |
0.1–14.3 (1.1) |
0.0–13.8 (1.7) |
0.0–13.6 (1.6) |
0.0–14.3 (1.7) |
| CD3−CD56+/CD16+ NK cells (mean) |
0.0–5.1 (0.7) |
0.0–6.1 (0.9) |
0.0–3.9 (0.07) |
0.0–6.9 (2.4) |
0.0–6.2 (0.7) |
| CD11c+ MCs (mean) |
0.0–2.0 (0.2) |
0.0–6.2 (0.3) |
0.0–6.2) (1.6) |
0.0–0.8 (0.9) |
0.0–4.2 (0.7) |
| CD68+CD163− macrophages (mean) |
0.3–9.1 (6.2) |
0.1–12.6 (4.4) |
0.7–38.0) (8.1) |
0.0–18.7 (3.6) |
0.0–18.7 (5.9) |
| CD68+CD163+macrophages (mean) |
0.0–5.8 (0.7) |
0.0–40.2 (3.7) |
0.0–28.1 (6.6) |
0.0–16.9 (2.4) |
0.0–16.9 (3.9) |
| expression of immune checkpoint and immune cell activation marker (MFI & percentage of positive cells) | |||||
| LAG3 MFI [mean] % [range (mean)] |
0.41 0–66(14.3%) |
1.53 0–100(49.9%) |
1.47 0–99(33.9%) |
1.01 0–98(25.1%) |
1.27 0–100(35.4%) |
| TIGIT MFI [mean] % [range (mean)] |
0.18 0–53(9.1%) |
0.21 0–60(3.6%) |
0.24 0–35(5.3%) |
0.17 0–89(7.1%) |
0.22 0–89(5.6%) |
| TIM3 MFI [mean] % [range (mean)] |
0.48 2–27(4.8%) |
0.43 1–99(43%) |
0.82 3–97(40.5%) |
0.69 0–99(65%) |
0.57 0–89(49.7%) |
| Gal-9 MFI [mean] % [range (mean)] |
0.22 0.7–26(31.1%) |
0.41 1–93(43.9%) |
0.84 2–97(34.6%) |
0.18 0–99(34.9%) |
0.39 0–99(36.9%) |
| PD-L1 MFI [mean] % [range (mean)] |
0.67 0–21(8.3%) |
1.86 0–99(41.9%) |
0.57 0–97(13.8%) |
0.98 0–98(20.2%) |
1.34 0–99(24.1%) |
| PD-L2 MFI [mean] % [range (mean)] |
0.87 0–2(0.6%) |
1.11 0–99(26.7%) |
1.24 0–95(10.7%) |
1.39 0–99(11.3%) |
0.84 0–99(15.8%) |
| PD-1 MFI [mean] % [range (mean)] |
1.22 0–4(1.4%) |
2.25 0–14(4.3%) |
1.22 0–19(4.5%) |
2.48 0–98(20.2%) |
0.58 0–98(10.2%) |
| CTLA4 MFI [mean] % [range (mean)] |
0.55 5–9(7.5) |
0.67 1–99(57.2%) |
2.07 16–96(74.8%) |
0.41 0–97(43.7%) |
0.76 0–99(51.7%) |
| CD80 MFI [mean] % [range (mean)] |
0.87 0–9(7.7%) |
0.71 1–99(56.2%) |
2.43 14–96(74.8%) |
0.95 0–98(53.7%) |
0.98 0–99(56.6%) |
| CD86 MFI [mean] % [range (mean)] |
0.09 0–4.4(1.4%) |
0.16 0–91(25.2%) |
0.28 1–97(33.1%) |
0.26 0–99(34.9%) |
0.19 0–99(31.1%) |
| CD28 MFI [mean] % [range (mean)] |
0.01 0–2.4(0.8%) |
0.23 0–53(13.9%) |
0.35 0–63(14.8%) |
0.14 0–52(8.1%) |
0.21 0–63(11.6%) |